TLSI profile · all as-reported value updates
TriSalus Life Sciences, Inc. (TLSI) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Net income | 2022 | 5,539,079 | -47,187,000 | -52,726,079 | -111.74% | revised comparative figure | 0001410578-23-000332 0001826667-24-000005 | 2 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2022 | 153,563 | 9,414,000 | 9,260,437 | +98.37% | revised comparative figure | 0001410578-23-000332 0001826667-24-000005 | 2 filed observations examined for this concept and period. |
| Stockholders' equity | 2022 | -13,266,586 | -177,132,000 | -163,865,414 | -92.51% | revised comparative figure | 0001410578-23-000332 0001826667-25-000070 | 4 filed observations examined for this concept and period. |
| Operating income | 2022 | -2,746,125 | -36,439,000 | -33,692,875 | -92.46% | revised comparative figure | 0001410578-23-000332 0001826667-24-000005 | 2 filed observations examined for this concept and period. |
| Operating cash flow | 2022 | -2,736,994 | -32,313,000 | -29,576,006 | -91.53% | revised comparative figure | 0001410578-23-000332 0001826667-24-000005 | 2 filed observations examined for this concept and period. |
| Stockholders' equity | 2021 | -16,717,103 | -129,605,000 | -112,887,897 | -87.10% | revised comparative figure | 0001410578-22-000252 0001826667-24-000005 | 3 filed observations examined for this concept and period. |
| Liabilities | 2022 | 13,654,332 | 34,319,000 | 20,664,668 | +60.21% | revised comparative figure | 0001410578-23-000332 0001826667-24-000005 | 2 filed observations examined for this concept and period. |
| Assets | 2022 | 20,187,776 | 21,995,000 | 1,807,224 | +8.22% | revised comparative figure | 0001410578-23-000332 0001826667-24-000005 | 2 filed observations examined for this concept and period. |
| Assets | 2023 | 25,725,000 | 24,598,000 | -1,127,000 | -4.38% | revised comparative figure | 0001826667-24-000005 0001826667-25-000070 | 3 filed observations examined for this concept and period. |
| Stockholders' equity | 2023 | -25,938,000 | -27,065,000 | -1,127,000 | -4.16% | revised comparative figure | 0001826667-24-000005 0001628280-26-015163 | 4 filed observations examined for this concept and period. |